B. Metzler seel. Sohn & Co. Holding AG Takes $1.32 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 23,817 shares of the biopharmaceutical company's stock, valued at approximately $1,323,000.

Several other institutional investors and hedge funds have also bought and sold shares of RARE. Quest Partners LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the third quarter worth $119,000. Swiss National Bank boosted its stake in shares of Ultragenyx Pharmaceutical by 9.1% in the third quarter. Swiss National Bank now owns 159,152 shares of the biopharmaceutical company's stock worth $8,841,000 after buying an additional 13,300 shares during the last quarter. Mutual of America Capital Management LLC acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $321,000. Natixis Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 290.0% in the third quarter. Natixis Advisors LLC now owns 52,562 shares of the biopharmaceutical company's stock valued at $2,920,000 after acquiring an additional 39,086 shares during the period. Finally, KBC Group NV boosted its position in Ultragenyx Pharmaceutical by 24.5% in the 3rd quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company's stock worth $143,000 after purchasing an additional 506 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Emil D. Kakkis sold 20,000 shares of the firm's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. This trade represents a 0.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Howard Horn sold 7,465 shares of the business's stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. This trade represents a 7.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,556 shares of company stock worth $1,515,967. Company insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Stock Up 2.7 %

RARE traded up $1.22 during trading on Friday, reaching $47.24. The company's stock had a trading volume of 593,872 shares, compared to its average volume of 978,390. The firm has a fifty day simple moving average of $53.14 and a two-hundred day simple moving average of $48.39. The company has a market cap of $4.36 billion, a price-to-earnings ratio of -7.30 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a 1 year low of $37.02 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping analysts' consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. During the same quarter in the previous year, the company posted ($2.23) earnings per share. The firm's revenue for the quarter was up 42.3% compared to the same quarter last year. As a group, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.21 EPS for the current fiscal year.

Analysts Set New Price Targets

RARE has been the topic of several analyst reports. Royal Bank of Canada restated an "outperform" rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. JPMorgan Chase & Co. dropped their target price on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating on the stock in a research report on Thursday. HC Wainwright increased their price target on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. Barclays reduced their target price on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an "overweight" rating for the company in a research note on Monday, August 5th. Finally, TD Cowen lifted their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $87.46.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.